BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24149177)

  • 21. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
    Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma.
    Gascoyne RD; Aoun P; Wu D; Chhanabhai M; Skinnider BF; Greiner TC; Morris SW; Connors JM; Vose JM; Viswanatha DS; Coldman A; Weisenburger DD
    Blood; 1999 Jun; 93(11):3913-21. PubMed ID: 10339500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
    Bavi P; Jehan Z; Bu R; Prabhakaran S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Al-Halouly T; Sairafi R; Uddin S; Al-Kuraya KS
    Br J Cancer; 2013 Nov; 109(10):2735-43. PubMed ID: 24129244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
    Kuda M; Kohashi K; Yamada Y; Maekawa A; Kinoshita Y; Nakatsura T; Iwamoto Y; Taguchi T; Oda Y
    Tumour Biol; 2016 Apr; 37(4):5213-23. PubMed ID: 26553361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
    Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
    Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis.
    Li Q; Zhang L; Jiang J; Zhang Y; Wang X; Zhang Q; Wang Y; Liu C; Li F
    BMC Med Genomics; 2019 Dec; 12(1):198. PubMed ID: 31870357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
    Nishimura R; Takita J; Sato-Otsubo A; Kato M; Koh K; Hanada R; Tanaka Y; Kato K; Maeda D; Fukayama M; Sanada M; Hayashi Y; Ogawa S
    Cancer Sci; 2013 Jul; 104(7):856-64. PubMed ID: 23578105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
    van Erp AEM; Hillebrandt-Roeffen MHS; van Houdt L; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH
    Target Oncol; 2017 Dec; 12(6):815-826. PubMed ID: 29067644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.
    Suzuki R; Kagami Y; Takeuchi K; Kami M; Okamoto M; Ichinohasama R; Mori N; Kojima M; Yoshino T; Yamabe H; Shiota M; Mori S; Ogura M; Hamajima N; Seto M; Suchi T; Morishima Y; Nakamura S
    Blood; 2000 Nov; 96(9):2993-3000. PubMed ID: 11049976
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.
    Ramanathan S; Sisodiya S; Shetty O; Prasad M; Parambil BC; Shah S; Ramadwar M; Khanna N; Laskar S; Qureshi S; Vora T; Chinnaswamy G
    Ecancermedicalscience; 2023; 17():1539. PubMed ID: 37138963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Abnormality of anaplastic lymphoma kinase gene and its expression in pediatric neuroblastoma].
    Chen S; Zhou C; Ma X; Gong L
    Zhonghua Bing Li Xue Za Zhi; 2014 Aug; 43(8):541-5. PubMed ID: 25346125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
    Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
    Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.